Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929943 | 0.98 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL1172463 | 0.84 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL1172180 | 0.83 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL3701630 | 0.81 | PKM (0.47) | CNR2CNR1 | |
| SCHEMBL11645221 | 0.80 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL11641149 | 0.80 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL10653170 | 0.79 | CNR1 (0.61) | CNR2CNR1 | |
| SCHEMBL1836711 | 0.78 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL1839235 | 0.78 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL1836097 | 0.78 | CNR2 (0.55) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2019079677-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-4131656-A | Intermediates for 5-(tertiary alkyl) resorcinol preparation | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR2 3/4885CNR1 1/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | CNR2 1/4885CNR1 2/4885 |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.